Tell the FDA What Psychedelic Care Should Look Like: Why Chronic Pain Must Be Included Before the Comment Deadline

The FDA is accepting public comments until October 5, 2026, on training, safety, access, and data standards for psychedelic care, but its framework is shaped around psychiatric conditions and largely overlooks chronic pain. Joe Moore argues that people with pain, clinicians, and researchers should document the care models they need, including physical therapy, neuromodulation, different staffing arrangements, and potentially supervised or at-home dosing when clinically appropriate. He highlights a veteran's reported recovery from complex regional pain syndrome after psilocybin-assisted treatment combined with physical therapy, while stressing that one case is not a clinical trial. The piece supports supervision and careful screening, but warns that psychiatric templates, physician response-time requirements, and depression-focused clinic models could exclude rural patients, limit research, and make access harder. It provides practical instructions for submitting comments and notes that public submissions should address only the FDA's stated scope.